Skip to content

ICU Medical ICUI Indefinite-Lived Intangible Assets

Indefinite-Lived Intangible Assets at other companies

Haemonetics logo
HaemoneticsHAE
$5.49M-18.7%
Abbott logo
AbbottABT

Other financials

Income statement

See full
Revenue$530.2M-12.3%
Gross profit$206.2M-1.8%
Operating income$13.6M+5.4%
Net income$30.1M+295%
EPS (diluted)$1.20+290%

Balance sheet

See full
Cash & equivalents$288.3M-0.5%
Total debt$1.4B-17.5%
Total equity$2.1B+6.3%
Total assets$4.0B-4.1%

Cash flow

See full
Operating cash flow$38.9M-24.2%
CapEx$11.3M-22.7%
Free cash flow$27.6M-24.8%

Valuation

See full
Market cap$3.39B-6.3%

Profitability

See full
Gross margin37.9%+2.8pp
Operating margin2%-0.7pp
Net margin-0.3%-0.2pp
FCF margin4.2%-1.2pp

Returns & leverage

See full
Return on equity-0.4%-0.2pp
Debt / equity0.6×-0.2×
Current ratio2.3×-0.3×

Where this comes from

Reported directly by ICU Medical in its filing.

Tagged under the XBRL concept us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwill.

The official record: ICU Medical’s 10-Q, filed May 7, 2026, on SEC EDGAR. View the filing →

Ask your AI about ICU Medical's indefinite-lived intangible assets.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is ICU Medical's indefinite-lived intangible assets?
ICU Medical (ICUI) reported indefinite-lived intangible assets of $7.58M in Q1 2026.
How has ICU Medical's indefinite-lived intangible assets changed year-over-year?
ICU Medical's indefinite-lived intangible assets decreased by 44.8% year-over-year, from $13.72M to $7.58M.
What is the long-term trend for ICU Medical's indefinite-lived intangible assets?
Over 5 years (2020 to 2025), ICU Medical's indefinite-lived intangible assets has grown at a -20.5% compound annual growth rate (CAGR), from $19.36M to $6.16M.
What does indefinite-lived intangible assets mean?
This represents intangible assets, such as iconic brand names or trademarks, that are expected to generate cash flows for an unlimited period. Unlike finite-lived assets, these are not amortized but are tested annually for impairment. They represent the core long-term value of the company's brand portfolio.